Literature DB >> 21640617

Diverse morphologic manifestations of cardiac allograft vasculopathy: a pathologic study of 64 allograft hearts.

Wei-hui Lu1, Kathy Palatnik, Gregory A Fishbein, Chi Lai, Daniel S Levi, Gregory Perens, Juan Alejos, Jon Kobashigawa, Michael C Fishbein.   

Abstract

BACKGROUND: Cardiac allograft vasculopathy (CAV) is a major limitation to the long-term success of cardiac transplantation. Although there are published descriptions of the lesions, there have been no studies delineating the pathology of CAV in a large series of patients who underwent retransplantation for CAV.
METHODS: We reviewed archival records and microscopic sections of surgically explanted hearts from 64 patients who underwent cardiac retransplantation: 54 adults (18 to 70 years old) and 10 children (3 to 15 years old). Vascular lesions were categorized as showing intimal fibromuscular hyperplasia, atherosclerosis and/or inflammation. The degree of luminal narrowing was estimated from gross descriptions and microscopic sections.
RESULTS: In total, 75% of hearts had evidence of acute cellular rejection, mostly mild. Intramyocardial arteries showed primarily intimal fibromuscular hyperplasia and inflammation with no atheromas present. Large and branch epicardial coronary arteries were narrowed in at least one artery of all hearts. Lesions in the epicardial coronary arteries were composed of intimal fibromuscular hyperplasia, atherosclerosis and/or inflammation affecting one or more vascular layers (intima, media and adventitia). Severe CAV with >75% luminal narrowing was seen in the LAD in 17% of hearts, the LCx in 17% and the RCA in 22% of hearts. Two hearts had severe narrowing of the left main coronary artery. Nineteen arteries had luminal thrombi. All hearts had narrowing of smaller epicardial branch coronary arteries that was often severe. Atheromas were present in arteries of adults and children; thus, not all atheromas could be considered pre-existing prior to transplantation. Both arteries and veins showed intimal hyperplasia and inflammation.
CONCLUSIONS: CAV is a pathologically multifaceted disorder that affects large and small epicardial coronary arteries of adults and children, with different types of lesions: intimal fibromuscular hyperplasia; atherosclerosis; and/or inflammation (vasculitis). Therapies to address this disease must take into account the protean nature of the vascular lesions.
Copyright © 2011 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21640617     DOI: 10.1016/j.healun.2011.04.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  21 in total

1.  Cardiac allograft vasculopathy: a complex multifactorial sequela of heart transplantation.

Authors:  Ana Maria Segura; L Maximilian Buja
Journal:  Tex Heart Inst J       Date:  2013

Review 2.  Lessons and limits of mouse models.

Authors:  Anita S Chong; Maria-Luisa Alegre; Michelle L Miller; Robert L Fairchild
Journal:  Cold Spring Harb Perspect Med       Date:  2013-12-01       Impact factor: 6.915

3.  Acute and chronic rejection: compartmentalization and kinetics of counterbalancing signals in cardiac transplants.

Authors:  A M K Kaul; S Goparaju; N Dvorina; S Iida; K S Keslar; C A de la Motte; A Valujskikh; R L Fairchild; W M Baldwin
Journal:  Am J Transplant       Date:  2015-01-12       Impact factor: 8.086

Review 4.  Coronary cardiac allograft vasculopathy versus native atherosclerosis: difficulties in classification.

Authors:  Annalisa Angelini; Chiara Castellani; Marny Fedrigo; Onno J de Boer; Lorine B Meijer-Jorna; Xiaofei Li; Marialuisa Valente; Gaetano Thiene; Allard C van der Wal
Journal:  Virchows Arch       Date:  2014-05-08       Impact factor: 4.064

5.  Association of periarterial neovascularization with progression of cardiac allograft vasculopathy and long-term clinical outcomes in heart transplant recipients.

Authors:  Hideki Kitahara; Kozo Okada; Shigemitsu Tanaka; Hyoung-Mo Yang; Kojiro Miki; Yuhei Kobayashi; Takumi Kimura; Helen Luikart; Paul G Yock; Alan C Yeung; Peter J Fitzgerald; Kiran K Khush; William F Fearon; Yasuhiro Honda
Journal:  J Heart Lung Transplant       Date:  2016-03-10       Impact factor: 10.247

Review 6.  Experimental models of cardiac transplantation: design determines relevance.

Authors:  William M Baldwin; Charles A Su; Thomas M Shroka; Robert L Fairchild
Journal:  Curr Opin Organ Transplant       Date:  2014-10       Impact factor: 2.640

Review 7.  Innate immune mechanisms in transplant allograft vasculopathy.

Authors:  Dan Jane-Wit; Caodi Fang; Daniel R Goldstein
Journal:  Curr Opin Organ Transplant       Date:  2016-06       Impact factor: 2.640

8.  Repeated episodes of thrombosis as a potential mechanism of plaque progression in cardiac allograft vasculopathy.

Authors:  Yoshiki Matsuo; Andrew Cassar; Jing Li; Andreas J Flammer; Byoung-Joo Choi; Joerg Herrmann; Rajiv Gulati; Ryan J Lennon; Soo-Jin Kang; Akiko Maehara; Hironori Kitabata; Takashi Akasaka; Lilach O Lerman; Sudhir S Kushwaha; Amir Lerman
Journal:  Eur Heart J       Date:  2013-06-19       Impact factor: 29.983

Review 9.  Cardiac allograft vasculopathy: current review and future research directions.

Authors:  Jordan S Pober; Sharon Chih; Jon Kobashigawa; Joren C Madsen; George Tellides
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

10.  TET2 Protects Against Vascular Smooth Muscle Cell Apoptosis and Intimal Thickening in Transplant Vasculopathy.

Authors:  Allison C Ostriker; Yi Xie; Raja Chakraborty; Ashley J Sizer; Yalai Bai; Min Ding; Wen-Liang Song; Anita Huttner; John Hwa; Kathleen A Martin
Journal:  Circulation       Date:  2021-06-11       Impact factor: 39.918

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.